Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

John Yu

John Yu

Chang Gung University, Taiwan

Title: Glycomics approaches to the studies of stem cells and development of glycan-targeted cancer immunotherapy

Biography

Biography: John Yu

Abstract

All cells carry an array of sugars or glycans that have the ability to modulate or mediate cellular interactions with other cells, and regulate development and functions of an organism. Nearly all aspects of biology are affected by glycan-mediated events. Glycans also participate in multiple fundamental cellular mechanisms that contribute to health and disease, yet they pose a great challenge to study as glycans are extremely heterogeneous, stereochemically complex, and glycosylation is not under direct genetic control. Here, we employed glycomic analysis to address two important biomedical issues: switching of glycosphingolipid core structures during differentiation of human embryonic stem cells (hESCs) and development of glycan-targeted cancer vaccine cancer. First, we will describe a systematic survey of expression profiles of GSLs and glycoproteins in hESCs and their differentiated derivatives along various lineage specifications. Based on MALDI-MS and MS/MS analyses, we have found expressions of a number of unique GSLs in the undifferentiated hESCs and induced pluripotent stem (iPS) cells, and also a close association of the GSL expressions with lineage-directed differentiation. Secondly, Globo H, a known biomarker for cancers, was found to be highly expressed in undifferentiated hESCs and iPS cells but disappeared upon differentiation, making Globo H to be an ideal target for cancer immunotherapy. Our recent findings of Globo H ceramide as immune checkpoint molecules and angiogenic factors provide further impetus for Globo H-targeted immunotherapy. These studies thus suggest that biosignatures unique for hESCs and iPS cells are potential targets for development of cancer therapeutics cancer vaccines

 

Speaker Presentations

Speaker PPTs Click Here